GEN InCode


GENinCode is a company dedicated to transforming cardiovascular health through genetics by providing advanced genomic testing, risk assessment tools, and personalized treatment pathways. With over 15 years of research and collaboration with leading institutions, GENinCode aims to prevent, diagnose, and treat cardiovascular disease using innovative technology that combines monogenic, polygenic, clinical algorithms, and artificial intelligence. The company operates in the UK, US, and Europe, and its products are validated by scientific and clinical teams to support healthcare practitioners in making informed decisions to improve patient outcomes.

Industries

biotechnology
health-care
life-science

Nr. of Employees

small (1-50)

GEN InCode

Oxford, Oxfordshire, United Kingdom, Europe


Products

Clinical genomic test suite for cardiovascular risk

A suite of in-vitro diagnostic tests that assess coronary genetic load (polygenic), monogenic causes of hypercholesterolemia and genetic thrombophilia, delivered from laboratory workflows and integrated into clinical reports.


Services

Genomic cardiovascular risk testing service

Clinical laboratory testing that combines targeted genotyping/sequencing, polygenic risk scoring and clinical data to produce individualized cardiovascular risk assessments and management recommendations.

Cloud-based clinical portal (test ordering, tracking, reporting)

Online portal for healthcare practitioners to request tests, capture clinical and genetic information, manage sample shipments, track testing status and retrieve reports.

CLIA- and regionally-accredited laboratory testing services

Laboratory testing services operated under CLIA certification and regional licensing to enable testing and report delivery across the United States and other jurisdictions where accredited.

Clinical implementation and customer support services

Clinical utility consultation, workflow design, ordering assistance, kit and logistics support, and lab service agreement setup for healthcare customers.

Early access and partnership program management

Coordination of early access programs, commercial partnerships and collaboration agreements to support market entry and scale-up.

Expertise Areas

  • Genomic risk assessment for cardiovascular disease
  • Polygenic risk score development and application
  • Monogenic variant testing for cardiometabolic disorders
  • Molecular diagnostics and targeted genotyping
  • Show More (4)

Key Technologies

  • Polygenic risk scoring
  • Monogenic variant genotyping
  • qPCR-based SNP genotyping
  • Genotyping and sequencing
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.